Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single and multiple ascending dose study of THN391 in healthy volunteers
NL-OMON53329Phase 1Recruiting
- Sponsor
- Therini Bio
- Start
- Apr 2023
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of THN391 in Dementia and neurological diseases (9 arms), sponsored by Therini Bio. Primary endpoints: Safety and tolerability of single ascending doses and Safety and tolerability of multiple ascending doses. Started Apr 2023; status: recruiting.
02
Drugs
THN391
03
Conditions
Dementianeurological diseases
Beyond the preview
Go deeper on NL-OMON53329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53329.